Program
Metformin
Also written as “metformin”, “Metformin XR” and “Fenofibrate /Metformin”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Obesity · Fasting · Polycystic Ovary Syndrome, led by 48 companies.
Drug pageMetformin: every studyMany companies study it; this page follows only the 215 they lead. All 1,290 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 290 open or running | phase 3since Nov 9, 2005 | Nov 9, 2005 | none ahead |
| Merck | 190 open or running | phase 4since Oct 9, 2009 | Feb 15, 2005 | none ahead |
| Sanofiits history only | 160 open or running | phase 4since Jul 28, 2006 | Sep 30, 2002 | none ahead |
| GlaxoSmithKlineits history only | 140 open or running | phase 4since Oct 17, 2005 | Sep 3, 2003 | none ahead |
| Takedaits history only | 120 open or running | phase 4since Sep 17, 2008 | Jul 30, 2008 | none ahead |
| Merck KGaA, Darmstadt, Germanyits history only | 90 open or running | phase 4since Dec 30, 2011 | Dec 30, 2011 | none ahead |
| Teva Pharmaceutical Industriesits history only | 90 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatrisits history only | 80 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| ADIUMits history only | 70 open or running | no phasesince Jun 3, 2026 | Jun 3, 2026 | none ahead |
| LG Chemits history only | 70 open or running | phase 3since Feb 6, 2013 | Aug 22, 2011 | none ahead |
| Novartisits history only | 70 open or running | phase 4since Aug 28, 2010 | Jul 31, 2008 | none ahead |
| Elcelyx Therapeuticsits history only | 60 open or running | phase 2since Aug 1, 2012 | Aug 1, 2012 | none ahead |
| Torrent Pharmaceuticalsits history only | 60 open or running | phase 1since Jul 21, 2009 | Jul 21, 2009 | none ahead |
| Dong Wha Pharmaceuticalits history only | 50 open or running | phase 1since Aug 5, 2014 | Aug 5, 2014 | none ahead |
| Bristol-Myers Squibbits history only | 40 open or running | phase 4since Oct 22, 2008 | May 3, 2002 | none ahead |
| Joint Stock Company "Farmak"its history only | 40 open or running | phase 1since Nov 8, 2021 | Nov 8, 2021 | none ahead |
| Laboratorios Silanes S.A. de C.V.its history only | 40 open or running | phase 4since Jul 15, 2009 | Jul 15, 2009 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Dec 15, 2008 | Jan 25, 2006 | none ahead |
| Gedeon Richter Plc.its history only | 30 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | none ahead |
| Sun Pharmaceutical Industriesits history only | 30 open or running | no phasesince Oct 22, 2008 | Oct 22, 2008 | none ahead |
| AET Laboratories Privateits history only | 20 open or running | no phasesince Mar 25, 2022 | Mar 25, 2022 | none ahead |
| AgelessRxits history only | 21 open or running | phase 3since Dec 18, 2024 | Oct 26, 2020 | none ahead |
| Aspargo Labsits history only | 22 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | none ahead |
| Biocineseits history only | 20 open or running | phase 4since Jun 2, 2011 | Apr 27, 2011 | none ahead |
| Boryung Pharmaceuticalits history only | 22 open or running | phase 1since Jul 16, 2025 | Jul 16, 2025 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Jul 9, 2010 | Jul 9, 2010 | none ahead |
| Geropharmits history only | 20 open or running | phase 1since Feb 26, 2018 | Feb 26, 2018 | none ahead |
| Handokits history only | 20 open or running | phase 4since Sep 21, 2011 | Sep 21, 2011 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 3since Aug 29, 2008 | Aug 29, 2008 | none ahead |
| Jeil Pharmaceuticalits history only | 20 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| NuSirt Biopharmaits history only | 20 open or running | phase 2since May 28, 2014 | May 28, 2014 | none ahead |
| Bio-innovaits history only | 11 open or running | phase 1since Dec 15, 2023 | Dec 15, 2023 | none ahead |
| Clinique Ovoits history only | 10 open or running | phase 3since Jul 9, 2012 | Jul 9, 2012 | none ahead |
| Cortendo ABits history only | 10 open or running | phase 1since Mar 18, 2019 | Mar 18, 2019 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 3since Oct 26, 2016 | Oct 26, 2016 | none ahead |
| Dalim BioTechits history only | 10 open or running | phase 1since Jan 29, 2013 | Jan 29, 2013 | none ahead |
| Disphar Internationalits history only | 10 open or running | phase 1since Aug 14, 2014 | Aug 14, 2014 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Nov 16, 2021 | Nov 16, 2021 | none ahead |
| Getz Pharmaits history only | 10 open or running | phase 4since Nov 29, 2021 | Nov 29, 2021 | none ahead |
| Hamad Medicalits history only | 10 open or running | no phasesince Apr 19, 2021 | Apr 19, 2021 | none ahead |
| Hanmi Pharmaceuticalits history only | 10 open or running | phase 1since Jan 23, 2013 | Jan 23, 2013 | none ahead |
| Health Clinicsits history only | 10 open or running | phase 3since Jul 22, 2014 | Jul 22, 2014 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Sep 15, 2010 | Sep 15, 2010 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| Lotus Pharmaceuticalits history only | 10 open or running | phase 3since Nov 19, 2010 | Nov 19, 2010 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
| Ozmosis Researchits history only | 10 open or running | phase 2since Feb 18, 2011 | Feb 18, 2011 | none ahead |
| PT. Pyridam Farma Tbkits history only | 10 open or running | no phasesince Feb 12, 2023 | Feb 12, 2023 | none ahead |
Also a collaborator on its studies: Parexel, PT Pharma Metric Labs, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly and Merck, S.L., Spain.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Feb 15, 2005.
- Feb 21, 2008Phase 2 study in Diabetes Mellitus, Type 2NCT00631488 · 146 enrolled
- Jan 26, 2009Phase 1 study in Diabetes Mellitus, Type 2NCT00830076 · 18 enrolled
- Jun 25, 2009Phase 1 study in Diabetes Mellitus, Type 2NCT00929201 · 61 enrolled
- Oct 9, 2009Phase 4 study in Diabetes Mellitus, Type 2NCT00993187 · 292 enrolled
- Dec 16, 2009Phase 3 study in Diabetes Mellitus, Type 2NCT01034111 · 30 enrolled
- Feb 24, 2010Phase 3 study in Diabetes Mellitus, Type 2NCT01076088 · 744 enrolled
- Mar 19, 2010Phase 1 study in Diabetes Mellitus, Type 2NCT01093794 · 28 enrolled
- Mar 1, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01545388 · 337 enrolled
- Mar 16, 2012Phase 1 study in Diabetes Mellitus, Type 2NCT01557504 · 25 enrolled
- Oct 4, 2012Phase 3 study in Diabetes Mellitus, Type 2NCT01702298 · 42 enrolled
- Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01760447 · 223 enrolled
- Aug 12, 2025Phase 1 study in HealthyNCT07121959 · 14 enrolled · United States
- Oct 27, 2025Phase 1 study in HealthyNCT07222098 · 16 enrolled · United States
- Apr 7, 2026Phase 1 study in HealthyNCT07530289 · 12 enrolled · United States
TargetBeta
“Mitochondrial complex I (NADH dehydrogenase) inhibitor; Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor”ChEMBL 37, by rule
Studies
All 19 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07530289Healthy · United States | 1 | Completed | May 23, 2026 | 12 |
| NCT07222098Healthy · United States | 1 | Completed | Dec 14, 2025 | 16 |
| NCT07121959Healthy · United States | 1 | Completed | Sep 13, 2025 | 14 |
| NCT01760447Diabetes Mellitus, Type 2 | 3 | Completed | Sep 17, 2019 | 223 |
| NCT01702298Diabetes Mellitus, Type 2 | 3 | Completed | May 29, 2013 | 42 |
| NCT01557504Diabetes Mellitus, Type 2 | 1 | Completed | Apr 29, 2014 | 25 |
| NCT01545388Diabetes Mellitus, Type 2 | 3 | Completed | Mar 12, 2013 | 337 |
| NCT01093794Diabetes Mellitus, Type 2 | 1 | Completed | Jun 2010 | 28 |
| NCT01076088Diabetes Mellitus, Type 2 | 3 | Completed | Dec 24, 2012 | 744 |
| NCT01034111Diabetes Mellitus, Type 2 | 3 | Completed | Oct 4, 2010 | 30 |
| NCT00993187Diabetes Mellitus, Type 2 | 4 | Completed | Oct 29, 2013 | 292 |
| NCT00929201Diabetes Mellitus, Type 2 | 1 | Completed | Mar 2008 | 61 |
| NCT00830076Diabetes Mellitus, Type 2 | 1 | Completed | Apr 30, 2009 | 18 |
| NCT00631488Diabetes Mellitus, Type 2 | 2 | Completed | Jan 2009 | 146 |
| NCT00543361Diabetes Mellitus, Type 2 | 3 | Terminated | Dec 2003 | 382 |
| NCT00541450Diabetes Mellitus, Type 2 | 3 | Completed | Jan 8, 2010 | 492 |
| NCT00532935Diabetes Mellitus, Type 2 | 3 | Completed | Oct 23, 2009 | 517 |
| NCT00482729Diabetes Mellitus, Type 2 | 3 | Completed | Nov 3, 2008 | 1,246 |
| NCT00103857Diabetes Mellitus, Type 2 | 3 | Completed | Jul 25, 2006 | 1,208 |
How it is read
Names in the registry
- “Metformin”, 95 entries
- “metformin”, 33 entries
- “Metformin XR”, 11 entries
- “Fenofibrate /Metformin”, 6 entries
- “Sitagliptin/Metformin FDC”, 5 entries
Codes read as this program: EFB0027.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 162 studies
- Diabetes Mellitus, 17 studies
- Obesity, 3 studies
- Fasting, 3 studies
- Polycystic Ovary Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.